Molecular Oncology
Volume 4, Issue 4 , Pages 357-368, August 2010

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer

  • Aslaug Aamodt Muggerud

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Institute of Clinical Medicine, University of Oslo, Norway
    • Present address: Oslo MS Genetics Group, Department of Neurology, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • ,
  • Michael Hallett

      Affiliations

    • McGill Centre for Bioinformatics, McGill University, Québec, Canada
    • Goodman Cancer Centre, McGill University, Québec, Canada
  • ,
  • Hilde Johnsen

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
  • ,
  • Kristine Kleivi

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland
  • ,
  • Wenjing Zhou

      Affiliations

    • Department of Surgery, Uppsala University Hospital, Sweden
  • ,
  • Simin Tahmasebpoor

      Affiliations

    • Department of Genetics and Pathology, Uppsala University Hospital, Sweden
  • ,
  • Rose-Marie Amini

      Affiliations

    • Department of Oncology and Pathology, Karolinska University Hospital, Sweden
  • ,
  • Johan Botling

      Affiliations

    • Department of Genetics and Pathology, Uppsala University Hospital, Sweden
  • ,
  • Anne-Lise Børresen-Dale

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Institute of Clinical Medicine, University of Oslo, Norway
  • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway
    • Department of Informatics, University of Oslo, Norway
    • Corresponding Author InformationCorresponding author. Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway. Tel.: +47 22781364; fax: +47 22781395.
  • ,
  • Fredrik Wärnberg

      Affiliations

    • Department of Surgery, Uppsala University Hospital, Sweden

Received 29 April 2010; received in revised form 14 June 2010; accepted 17 June 2010. published online 05 July 2010.

Abstract 

Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer where cells restricted to the ducts exhibit an atypical phenotype. Some DCIS lesions are believed to rapidly transit to invasive ductal carcinomas (IDCs), while others remain unchanged. Existing classification systems for DCIS fail to identify those lesions that transit to IDC. We studied gene expression patterns of 31 pure DCIS, 36 pure invasive cancers and 42 cases of mixed diagnosis (invasive cancer with an in situ component) using Agilent Whole Human Genome Oligo Microarrays 44k. Six normal breast tissue samples were also included as controls. qRT-PCR was used for validation. All DCIS and invasive samples could be classified into the “intrinsic” molecular subtypes defined for invasive breast cancer. Hierarchical clustering establishes that samples group by intrinsic subtype, and not by diagnosis. We observed heterogeneity in the transcriptomes among DCIS of high histological grade and identified a distinct subgroup containing seven of the 31 DCIS samples with gene expression characteristics more similar to advanced tumours. A set of genes independent of grade, ER-status and HER2-status was identified by logistic regression that univariately classified a sample as belonging to this distinct DCIS subgroup. qRT-PCR of single markers clearly separated this DCIS subgroup from the other DCIS, and contains samples from several histopathological and intrinsic molecular subtypes. The genes that differentiate between these two types of DCIS suggest several processes related to the re-organisation of the microenvironment. This raises interesting possibilities for identification of DCIS lesions both with and without invasive characteristics, which potentially could be used in clinical assessment of a woman’s risk of progression, and lead to improved management that would avoid the current over- and under-treatment of patients.

Keywords: DCIS, Molecular subtypes of breast cancer, Progression, Gene expression

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(10)00059-1

doi:10.1016/j.molonc.2010.06.007

Molecular Oncology
Volume 4, Issue 4 , Pages 357-368, August 2010